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ABSTRACT 
Background: Idiopathic nephrotic syndrome (INS) is the commonest type of nephropathy 
seen in children. The histopathological types and steroid response patterns of INS have been 
changing over the years and this has been attributed to differences in ethnicity and 
geographical location.  The aim of this study was to determine the steroid response pattern, 
renal histopathology and complications in a cohort of the children treated for INS by the 
Division of Paediatric Nephrology, CMJAH, Johannesburg, South Africa between 2004 and 
2013. 
Method: A retrospective study was carried out to review the records of 163 children between 
the ages of 2 and 16 years managed for INS over a 10 year period. 
Results: The majority (111) of the 163 children were of the black racial group. There were 
97 boys and 66 girls. The mean age of onset was 5.3 years ± 2.8, with the highest rate of INS 
seen in the 2-6 year age group (71.2%). Only 132/163 had a renal biopsy performed (MCD 
52.3%, FSGS 43.2%, MesPGN 4.5%). The black race had a similar rate of MCD (38.8%) and 
FSGS (37.8%), while the white race had a higher rate of MCD (64.3%) when compared to 
FSGS (14.3%). Ninety four (57.7%) patients were steroid sensitive (SSNS) while 69 patients 
(42.3%) were steroid resistant (SRNS). Minimal change disease was the most common 
histopathological type seen in SSNS (60%), while FSGS was the most common observed in 
patients who had SRNS (65.2%). There was a statistically significant association between the 
various steroid response patterns and the different histopathological types. The highest rate of 
resistance to all treatment after a mean follow up of 60 months was seen among children of 
the mixed race and black racial groups (50.0% and 40.5% respectively). Stunted growth 
(52.1%), hypertension (47.2%) and reduced eGFR (25.8%) were the most common 
complications observed. 
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Conclusions: There appears to be an increase in the rate of FSGS in all the racial groups, and 
an increase in the rate of MCD in the black race group, when compared to previous South 
African studies. Furthermore, steroid response was also observed to have increased 
significantly among the black racial group when compared with previous studies. Although 
hypertension was the most common complication observed in our cohort, a very high rate of 
stunted growth was also observed. This may be due to the significant number of patients with 
reduced eGFR, SRNS and FSGS in our cohort. The use of long term steroid therapy may 
have contributed to this high rate.  
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NOMENCLATURE 
 
Anti-ds DNA Anti-double stranded DNA 
AKI Acute kidney injury 
ANA Antinuclear antibody 
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ESR Erythrocyte sedimentation rate 
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INS Idiopathic nephrotic syndrome 
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KDIGO Kidney Disease Improving Global Outcomes 
LDL Low density lipoprotein 
LRTI Lower respiratory tract infection 
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MCD Minimal change disease 
MMF Mycophenolate Mofetil 
MesPGN Mesangial proliferative glomerulonephritis  
NOS Not otherwise specified 
NS Nephrotic syndrome 
PTB Pulmonary tuberculosis 
RTI Respiratory tract infection 
SDNS Steroid dependent nephrotic syndrome 
SRNS Steroid resistant nephrotic syndrome  
SSDs Steroid sparing drugs 
SSNS Steroid sensitive nephrotic syndrome 
Tacro Tacrolimus 
TEP Thromboembolic phenomenon  
uPCR Urinary protein/creatinine ratio 
URTI Upper respiratory tract infection  
UTI Urinary tract infection  
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1. INTRODUCTION 
Approximately 90% of children presenting between the ages of two and ten years with 
nephrotic syndrome (NS) will be diagnosed as having idiopathic nephrotic syndrome (INS). 
(1-3) Most cases of NS that present in the first year of life are diagnosed as congenital NS, 
and above the age of ten years most of the cases will be diagnosed as having secondary NS. 
(1,2,4)   
The spectrum of INS in African countries seems to be different from other parts of the world 
suggesting that an interaction of genetic and environmental factors plays an important role in 
the pathogenesis of INS. (5-8) 
A significant number of cases of INS are usually steroid sensitive, while some cases will be 
diagnosed as having steroid unresponsive disease. (1,9)  
The histopathological pattern of presentation, its changing pattern and advances in the 
treatment of childhood INS have been reported widely. (10-16) Childhood INS is most 
commonly caused by one of several idiopathic diseases: Minimal-change disease (MCD), 
focal segmental glomerulosclerosis (FSGS) and, less commonly, mesangial proliferative 
glomerulonephritis (MesPGN). (1,2,17) These various histopathological features have been 
strongly associated with differences in response to corticosteroid therapy, subsequent clinical 
course and prognosis. (9,18,20) 
Many authors feel that the histopathological pattern of INS has been changing despite a stable 
incidence of the disease in the last 30 years. This is as noted by the increasing reported 
incidence of FSGS. (14,15,20) 
Although the use of corticosteroids as initial therapy for INS is accepted internationally, 
steroid sparing drugs (SSDs) are indicated in steroid resistant nephrotic syndrome (SRNS), 
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frequently relapsing NS, in cases with severe side effects of steroid therapy, in children at 
risk for toxicity and in patients with poor compliance. (18,21)  
Various complications have been attributed to INS and as a result of adverse effects of 
treatment. (1,22) These include infections, thromboembolic phenomenon (TEP), acute kidney 
injury (AKI), hypertension and declining renal function. Common side effects such as the 
development of cushingoid features and obesity, hypertension, growth retardation, 
ophthalmologic disorders, behavioral changes and osteoporosis may also be seen as a result 
of corticosteroid therapy. (22-24) 
A better understanding of the presentation, the steroid response pattern and the 
histopathological pattern of childhood INS is very important in determining future guidelines 
for effective management of the disease.  
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1.1 Literature Review 
Idiopathic nephrotic syndrome (INS) is the commonest type of nephrotic syndrome (NS) seen 
in children. (18,25) It is characterized by a combination of NS with non-specific 
histopathological abnormalities seen on renal biopsy (1).  
While INS develops in the absence of an underlying etiology, many conditions have been 
reported to be associated with INS. These include, for example, upper respiratory tract 
infections (URTI), allergic reactions, malignancies, and Eosinophilic Lymphoid Granuloma. 
(25-27) However, the question still remains as to whether these factors are real causes, or just 
precipitating agents, of the disease.  
Idiopathic nephrotic syndrome has been reported as being fifteen times more common in 
children than adults. (28) The male to female ratio is usually around 2:1 among younger 
children and then becomes closer to 1:1 in adolescence. The most common age of 
presentation is 2-6 years. (1,2,9)  
The reported incidence of INS varies with the ethnic origin and different geographical 
locations of the different cohorts studied (5,29,30) and, although the worldwide incidence of 
INS has been stable for the last 30 years, many authors feel that the histopathological pattern 
has been changing as noted by the increasing reported incidence of FSGS. (10-12) The 
annual incidence of INS in the USA and Europe is 1-3 cases per 100 000 children, with a 
prevalence of 16 per 100 000 children. (29,30) Similar findings were reported from New 
Zealand. (17)   
In a report from the United Kingdom, INS was 6 times more common in children of Asian 
origin than in those of European origin (13). This finding was supported by a study from 
India. (31) In the United States a recent review of children with INS in Houston, Texas 
revealed that race had an important impact on the histological lesion seen in INS. (11) They 
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found only 11% of the Hispanic population, and 18% of Caucasians, had FSGS compared 
with African American children (47%). (11) The spectrum of INS in African countries seems 
to be different from the other parts of the world which suggests that the interaction of genetic 
and environmental factors play an important role in the pathogenesis of INS. (5-8) 
 
1.1.1 Pathogenesis 
The pathogenesis of INS remains unclear, however evidence suggests that a defect in the 
immune system plays an important role. (32,33)  
Studies on children with INS have found increased cytokines (IL1, IL2, IL4, IL12, IL13, 
IL18, and tumour necrosis factor alpha (TNFα)) in the serum, which may all directly act on 
the glomerular capillary wall. (32)  
There is also evidence for a glomerular permeability factor produced by T cells. (33) Also, 
INS patients have been found to have high levels of circulating B lymphocytes, IL2, soluble 
IL2 receptor and interferon gamma levels during a relapse episode. (34,35) 
 All of these observations point to the role of the immune system in the pathogenesis of INS, 
however the exact mechanism which affects the immune system, and how the cells are 
involved (cytokines or immunological factors), is still unknown. (36) 
 Additional evidence that NS has an immunological basis is the beneficial effect of 
immunosuppressive drugs in INS patients. (36,37)  
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1.1.2 Clinical presentation and complications of NS 
INS is often preceded by an upper respiratory tract infection (URTI) followed by the sudden 
onset of periorbital swelling. (23,29) Anasarca may develop with ascites, pleural and 
pericardial effusions. (1) Oedema of the scrotum, penis and labiae may also be seen. (1,2) 
Abdominal pain is often an associated feature and may be as a result of a bacterial peritonitis, 
visceral oedema, gut ischaemia and rarely pancreatitis and even renal vein thrombosis. 
(29,38) Severe intravascular hypovolemia secondary to the sudden fall of plasma albumin 
may cause acute kidney injury (AKI). (2) Gross haematuria is not a feature of INS unless 
there has been a renal vessel thrombosis, although microscopic haematuria may be seen up to 
23% of patients with MCD and even more than that in patients with other histopathological 
types. (18) Hypertension may be present with INS. (1,2,18) Thromboembolic phenomenon 
(TEP) such as deep vein or arterial thromboses and pulmonary embolism  may also occur 
during the first attack or during a relapse. (1) 
Although all the drugs used in the management of INS have known side effects, because of 
their ubiquitous use in INS, those of the glucocorticoid group deserve special mention. These 
include the development of cushingoid features and obesity (42%), hypertension (10%), 
growth retardation (8%), ophthalmologic disorders including posterior subcapsular cataracts 
and raised intraocular pressure (6%), behavioral changes including aggression, inattention, 
hyperactivity and sleep disturbances (4%) and osteoporosis (2%). (22-24) 
 
1.1.3 The clinical course of INS 
The clinical course of INS is described according to the level of steroid responsiveness. One 
third of patients will experience a single attack and are cured after a course of corticosteroid. 
(24,29) About 10% - 20% of INS children will suffer a relapse several months after stopping 
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the treatment. (39) In these patients cure usually takes place after three or four of these 
episodes, which all respond to a standard course of corticosteroids. These patients are 
described as having infrequently relapsing NS, (IFRNS). (39) The remaining 40–50% of 
children with steroid sensitive NS will relapse frequently (FRNS) and some may even 
become steroid dependent (SDNS) and will be at risk for steroid toxicity. Patients who 
continue to respond to steroids have a minimal risk of developing chronic renal failure. 
(24,39)  
In INS, patients with FSGS on biopsy have been reported as having the highest risk for 
steroid resistance (SRNS), although a minority of steroid resistant patients will have MCD on 
biopsy. (40,41)  
The prognosis of SRNS is poor and these patients have a high risk for developing disease 
related complications and progression to chronic kidney disease. Steroid resistant nephrotic 
syndrome (SRNS) accounts for 10%–20% of end-stage kidney disease (ESKD) in children 
and has a high recurrence rate after kidney transplantation. (41,42) 
 
1.1.4 Laboratory evaluation 
a. Urinalysis:  
All cases of suspected NS should have a urine dipstick test performed. The finding of 
more than 3+ protein on dipstick test is highly suggestive of significant proteinuria and 
the urine should then be sent for an early morning urinary protein/creatinine ratio (uPCR) 
estimation with the nephrotic range reported as 0.2–0.4 g/mmol. (43)  
 
 
                                                                                       7 
 
b. Blood chemistry: 
Serum proteins are markedly reduced and the serum albumin concentration usually falls 
below 20 g/l. (1) Serum lipids are usually increased. Total cholesterol and LDL 
cholesterol are elevated while HDL cholesterol remains unchanged or low. (44) This 
results in an increased LDL:HDL cholesterol ratio. (44) 
Serum electrolytes are usually within the normal range although the serum sodium may 
be decreased (pseudohyponatraemia). (1) Serum potassium may be high in oliguric 
patients. Serum calcium is consistently low but the ionized calcium is usually normal and 
serum calcitriol is normal. (1,2) Blood urea nitrogen and creatinine concentrations are 
usually within the normal range. (2) 
c. Haematology:  
Haemoglobin and haematocrit are often increased due to plasma volume contraction. (1) 
Thrombocytosis may be seen in children with INS. (2)  
d. Serology:  
C3 and C4 complement level, antinuclear antibody (ANA) and anti-double stranded DNA 
(Anti-ds DNA) are all important tests to perform in INS to exclude secondary causes of 
NS. (1, 2)  
e. Virology screening:  
Hepatitis B, C and HIV antibody testing is also recommended as all of these viruses can 
cause secondary NS. In addition, the immunosuppressive therapy used in INS may result 
in a flare of the viral activity. (1, 2) Some centers obtain a Varicella IgG titer too, to allow 
for pre therapy immunization with Varicella-Zoster Virus vaccine in unexposed patients. 
f. Tuberculosis screening is also often performed prior to initiating immunosuppressive 
therapy. (1, 2)  
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Histopathology 
Although different units have different protocols for performing renal biopsies in children 
with INS, most units would agree with the following indications and would perform a renal 
biopsy in the following group of patients (1,2,21): 
1. Children with NS in whom the onset of the disease occurs before the age of 1 year 
and after the age of 10 years.  
2. Children who remain unresponsive to an initial course of corticosteroid therapy of 
more than 6 weeks, or who develop secondary steroid resistance (SRNS).  
3. Children who respond to corticosteroid therapy but then go on to develop more than 
three relapses over a one year period (FRNS). 
4. Children who have atypical features of NS at the time of diagnosis (macroscopic 
haematuria, hypertension, persistent renal insufficiency, and low C3 component of 
complement).  
Childhood INS is most commonly caused by one of two idiopathic diseases: Minimal change 
disease (MCD) is the most common histopathological lesion seen and accounts for 85% of 
INS. More than 95% of these cases respond to steroid therapy and will not need a renal 
biopsy. (1,14,45) Minimal change disease shows normal glomeruli with normal capillary 
walls and normal cellularity on light microscopy. (1) The second most common histological 
type of INS is FSGS. (1,2,29) This presents as a heterogeneous disease, with both immune 
and non-immune causes, and has been reported to be less frequent in young children (20 %). 
(1,2,46) FSGS implies an irreversible scarring process taking place in the glomeruli. (46,47) 
There are five histological variants of FSGS (collapsing, cellular, glomerular tip, perihilar 
and not otherwise specified (NOS)) which may have clinical impact on response to treatment 
and prognosis. (48,49) For example, glomerular tip lesions appear to have better outcomes 
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than the collapsing glomerulopathy type which predominates in black patients. (48,49) 
Recent genetic studies highlight the fact that FSGS is associated with several genes that may 
play a critical role in podocyte function and the glomerular filtration barrier. (50-52) 
However a mechanism for the glomerular abnormalities in MCD, and idiopathic FSGS with 
relapse, remains unknown. (53) A third distinct type, mesangial proliferative glomerulopathy 
(MesPGN) is rare in children. (1,2) 
In all cases of INS no significant deposition of immunoglobulin or complement is noted in 
the kidney tissue. (1)  
 
1.1.6 Treatment 
 The initial protocols emphasizing the role of corticosteroids in inducing remission of INS 
were established between 1967 and 1974 by the International Study of Kidney Disease in 
Children (ISKDC), and were subsequently modified by the Arbeitsgemeinschaft für 
Pädiastrische Nephrologie (APN). (3,54,55) Although the use of corticosteroids as initial 
therapy for INS is accepted internationally there are many areas of uncertainty in the 
management of INS. Two American surveys demonstrated wide practice variation in all 
aspects of INS treatment and many clinical practice guidelines for management of childhood 
INS have been published over the years e.g. France (2008), North America (2009), and India 
(2008). (56-60) 
In 2012, the Kidney Disease Improving Global Outcomes (KDIGO) published an 
international clinical practice guideline for the management of INS. (21) The goal of this 
guideline was to improve quality of care by helping clinicians to know and understand the 
evidence that determines practice. However, many reports in the literature suggest that actual 
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clinical practice deviates from what the evidence recommends partly due to the absence of a 
systematic approach when it comes to translating existing evidence into practice. 
(56,57,61,62)  
1. Symptomatic treatment 
Children with INS may develop significant complications and therefore therapy is also 
aimed at reducing complications. The use of antimicrobial prophylaxis, treatment of 
infection, immunization, antithrombotic therapy, antihypertensive therapy, 
conservative management of oedema and management of dyslipidaemia may all be 
indicated for symptomatic treatment.  (63)   
 
2. Specific treatment 
Although remission without treatment may occur within 1 or 2 weeks in up to 5% of 
cases, corticosteroid therapy is recommended as the initial treatment for all children 
who meet the criteria for INS. (64) It is important to remember that any underlying 
infection must be treated before starting corticosteroids to prevent the risk of 
overwhelming sepsis during treatment. (3,59) It should also be kept in mind that an 
occult infection may be responsible for steroid resistance. (1) 
 
a. Treatment of the initial episode:  The ISKDC has reported that approximately 
90% of responders will go into remission within 4 weeks after starting 
corticosteroids and that less than 10% will go into remission after 6–8 weeks of a 
daily regimen. (3) The standard regimen according to KDIGO 2012 consists of 
prednisone, 60 mg/m
2
/day or 2 mg/kg/day (up to a maximum of 60 mg/day), in 
divided doses for 4 weeks followed by 40 mg/m
2
/dose or 1.5 mg/kg/dose (up to a 
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maximum of 40 mg/day on alternate days) in a single dose for 4 weeks and 
continued for 2-5 months with tapering of the dose. (21) 
The duration of the corticosteroid course has come under debate recently. The APN 
and other several controlled studies documented that the relapse rate was reduced 
with longer courses of corticosteroid therapy. (55,65,66) However, a recent 
multicenter randomized placebo controlled trial showed that although extending 
the initial prednisone treatment from 3 to 6 months may delay the first relapse, it 
does not appear to have an impact on the occurrence of frequent relapses nor alter 
the course of the disease. (67)  
 
b. Treatment of relapses: The risk for a relapse is higher in male children and in 
those aged less than 5 years at onset. (1) Corticosteroid therapy should be started 
immediately if proteinuria recurs, and then persists for more than 3 days, to avoid 
any associated complications. (3)  The KDIGO has proposed that infrequent 
relapse episodes should be treated with daily prednisone 60 mg/m
2
/day or 2 
mg/kg/day (up to a maximum of 60 mg/day) until the child has been in remission 
for 3 days, followed by prednisone 40 mg/m
2
/dose or 1.5 mg/kg/dose (up to a 
maximum of 40 mg/day) on alternate days for at least 4 weeks. (21) Treatment of 
frequent relapses and SDNS consists of daily prednisone (60 mg/m
2
/day) until the 
child has been in remission for at least 3 days, followed by alternate-day 
prednisone for at least 3 months, then decreasing doses until a dose of 10-30 
mg/m
2
/dose or 0.3-1 mg/kg/dose has been reached, on alternate days or as daily 
dosing in cases where alternate-day prednisone therapy has not been effective. (21) 
Another option available for the treatment of frequent relapses and SDNS is the use 
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of steroid sparing drugs (SSDs), particularly where patients have developed steroid 
related adverse effects. (21) 
c. Treatment of steroid resistant INS: The treatment of SRNS remains a difficult 
challenge. Most children with SRNS have received intensive treatment regimens 
and many of them have been over treated. (8,40,41) There is no diagnostic marker 
that can be used as a predictor for steroid responsiveness or resistance in INS. 
(8,41) SRNS patients with FSGS on biopsy, and who have not had genetic 
screening performed, may respond to cyclosporine. Complete remission may be 
achieved in 31%, and partial remission in 38%, during a 6 month course of therapy. 
(68-70) Cyclophosphamide use in SRNS has not been shown to have any effect on 
inducing remission. (1,2,40) The use of methylprednisolone in SRNS is 
controversial. Mendoza et al. found a high rate of remission and a reduction in the 
incidence of end-stage kidney disease from 40% to 5% using historical controls, 
when he administered methylprednisolone in SRNS patients. (71) Despite this 
finding, Waldo et al. found that pulse methylprednisolone was not effective in 
inducing remission in black patients. (72) The rate of remission is higher in 
patients with late onset SRNS who have responded to a steroid sparing agent 
compared with those who have SRNS from the outset. (8) Tacrolimus has also 
been shown to be effective for children with SRNS with a complete remission rate 
of 81%, and a partial remission rate of 13%, described. (73,74)  
 
d. Steroid sparing drugs (SSDs): The indications to use SSDs in children with INS 
include; severe side effects of corticosteroid therapy, children at risk for toxicity, 
multiple severe relapses and poor compliance. (21) These drugs include: 
Levamisole, alkylating agents (Cyclophosphamide, Chlorambucil), calcineurin 
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inhibitors (Cyclosporin, Tacrolimus), antiproliferative agents (Azathioprine, 
Mycophenolate Mofetil (MMF)) and Rituximab. 
 
In conclusion, INS remains an important cause of childhood glomerulopathy. Its different 
patterns of presentation, different types of histopathology and different responses to treatment 
are attributed to ethnic and geographical variation. Recent studies indicate an increasing 
incidence of steroid resistance in children with INS and these patients have a high risk for 
developing disease related complications and progression to chronic kidney disease. A better 
understanding of the disease along with improved management may transform the outcome 
of childhood INS. 
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1.2 Justification for the study 
Idiopathic NS makes up a significant number of children treated in our clinic, and the 
progression of the disease in black South African children is still not fully understood. Data 
from units in Sub-Saharan Africa suggests that INS is less common among black African 
children and also that the clinical behavior and response to therapy appears to be different 
when compared with children in the western world. These data suggest that genetic and 
environmental factors are important in the pathogenesis of INS. (5-8) 
A study from Durban, South Africa found that, in black South African children, the 
glomerular proliferative change was the commonest lesion seen and that corticosteroids were 
found to be ineffective. (5) Our impression is that the clinical picture of our patients is 
different from that reported in previous studies on African children. (5-7,10) In addition, 
although much research has been done on INS in the past, there are still gaps in our 
knowledge of this disease especially with regards to our unique patient population. It is for 
these reasons that we have undertaken to perform this study.  
We planned to undertake this research to try to increase our knowledge of this condition, 
especially as it pertains to our patient cohort. We hoped that the findings of this study would 
give us more information on this topic and might enable us to identify new prognostic 
indicators and perhaps enable us to develop better approaches to the management of this 
condition, specifically for our patients. 
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1.3 Aim 
To determine the steroid response pattern, renal histopathology and complications in a cohort 
of children treated for INS by the Division of Paediatric Nephrology, CMJAH, Johannesburg, 
South Africa between 2004 and 2013. 
 
Specific objectives 
(1) To determine the rate of the different renal histopathological patterns seen in the study 
cohort on renal biopsy. 
(2) To determine the rate of the different steroid response patterns of the study cohort. 
(3) To determine if there is any association between the racial groups in the study cohort 
and objectives 1 and 2. 
(4) To document any complications that might have developed namely hypertension, 
infections, thromboembolic phenomena (TEP), acute kidney injury (AKI), 
hypothyroidism, psychosis, obesity, cataracts, stunted growth and a reduced eGFR.  
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2.  MATERIALS AND METHODS 
The study was carried out in the Division of Paediatric Nephrology of Charlotte Maxeke 
Johannesburg Academic Hospital (CMJAH). The Division provides a comprehensive tertiary 
and quaternary paediatric nephrology service primarily to children referred from Gauteng and 
its surrounding provinces.  
2.1 Study design 
The study was a descriptive retrospective cohort study.  
2.2 Study population  
All patients between 2 and 16 years of age with Idiopathic Nephrotic Syndrome treated by 
the Division of Paediatric Nephrology at CMJAH between January 2004 and December 
2013. 
2.3 Selection criteria 
2.3.1 Inclusion Criteria 
1. Only children between the ages of 2 and 16 years were included in the study 
2. Only children who had at least 6 months of follow up after onset of the disease were 
included in the study 
3. Only children who fulfilled all the criteria for INS at the initial presentation 
(generalized oedema, hypoalbuminaemia (serum albumin < 25 g/l), significant 
proteinuria (uPCR ˃ 0.2 g/mmol) with, or without, hypercholesterolemia (serum 
cholesterol > 5.2 mmol/l)) were included in the study 
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2.3.2 Exclusion Criteria 
1. Any files with absent or incomplete data 
2. Patients with systemic diseases or infections known to cause secondary nephrotic 
syndrome  
3. Children with congenital nephrotic syndrome (onset <3 months of age)  
4. Children with evidence of chronic renal impairment prior to the diagnosis of INS 
(estimated glomerular filtration rate (eGFR) ≤60 mL/min/1.73 m2) 
5. Children with a family history of nephrotic syndrome or chronic kidney disease 
 
2.4 Sample size 
The files of 180 patients with INS were identified from the clinic data base. 
Only 163 of these patients met all the study selection criteria.  
Seventeen patients were excluded from the data analysis (8 were above the age of 16 years 
and had been transferred to adult unit, 2 files had incomplete data and 7 children were still 
within the 6 month period post onset of the disease) 
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2.5 Study procedure 
The individual patient records of the Division of Paediatric Nephrology of CMJAH are kept 
in patient files in a secure filing room in the division. These files were screened for patients 
who fulfilled the selection criteria. Data was then extracted from the patient files that met the 
study criteria by the primary investigator and entered onto a data capture sheet. (Appendix 
A).  
Information extracted included the following clinical information: anthropometry (weight and 
height), blood pressure, the presence of oedema, ascites, pleural and/or pericardial effusions, 
the presence of infection (URTI, LRTI, UTI, peritonitis) and the presence of TEP. The 
dipstick urinalysis was used to document the presence of haematuria.  
In addition, all pertinent laboratory data were interpreted and captured where relevant as 
follows; remission, relapse, the presence of infection, hypercholesterolaemia, haematuria, 
hyperglycaemia, hypothyroidism, acute kidney injury, reduced eGFR, etc. 
 Additional information recorded on the data capture sheet included the age of the child at the 
time of data capture, the age at presentation, sex, race, the follow up period (the period from 
the date of onset of the disease up to the time of data collection), the steroid response pattern 
of INS (SSNS and SRNS), the number of relapses per year (FRNS and IFRNS), the use of 
steroid sparing drugs (SSDs), the type of SSDs (alkylating agents [cyclophosphamide or 
chlorambucil], calcineurin inhibitors [cyclosporine or tacrolimus], Mycophenolate mofetil 
[MMF] and rituximab), the presence of other complications (e.g. hypertension, growth 
stunting, psychosis, obesity, cataracts and TEP), and the outcome to treatment (sustained 
remission without steroid, in remission with a small dose of steroid, in remission with 
steroids and SSDs, FRNS, SRNS and resistance to all treatment). In cases which had a renal 
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biopsy performed the histopathological type of INS was documented (MCD, FSGS, 
MesPGN). 
All the relevant information was then entered into an Excel database. 
Strict patient confidentiality was maintained. All patients were allocated a study number and 
no patient was identified by name or hospital number on the database. 
2.6 Definition of terms 
1. Follow up period: The period from the date of the onset of disease up until the time of 
data collection. 
2. Steroid response pattern (21): 
a. Steroid sensitive nephrotic syndrome (SSNS) (initial responder): Attainment 
of remission within initial 4 weeks of corticosteroid therapy. 
b. Steroid dependent nephrotic syndrome (SDNS): Two consecutive relapses 
during corticosteroid therapy, or within 14 days of ceasing therapy. 
c. Steroid resistant nephrotic syndrome (SRNS) (initial non responder/steroid 
resistance): Failure to achieve complete remission after 8 weeks of 
corticosteroid therapy. 
3. Remission (21): Urine protein/creatinine ratio (uPCR) < 200 mg/g (< 0.02 g/mmol) or 
<1+ of protein on urine dipstick for 3 consecutive days.  
4. Relapse: Urine PCR ≥ 2000 mg/g (≥ 0.2 g/mmol) or ≥ 3+ protein on urine dipstick for 3 
consecutive days (21): 
a. Infrequently relapsing nephrotic syndrome (IFRNS): One relapse 
within 6 months of initial response, or one to three relapses in any 12 
month period.  
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b. Frequently relapsing nephrotic syndrome (FRNS): Two or more 
relapses within 6 months of initial response, or four or more relapses in 
any 12 month period. 
5. Types of steroid sparing drugs (SSDs): 
   CP - Cyclophosphamide (Cytoxan®)    
  Chlor - Chlorambucil (Leukeran®)   
  CyA - Cyclosporine (Neoral®)   
  Tacro - Tacrolimus (Prograf®)   
  MMF - Mycophenolate mofetil (Cellcept®)   
  Other – SSD e.g.: Levamisole, Rituximab. 
6. Hypertension (75): A blood pressure greater than the 95th percentile for sex, age and 
height using standard charts or any patient on antihypertensive treatment. 
7. Stunted growth (76): A height that is 2 standard deviations (SD) or more below the mean 
for children of that sex and chronologic age. This corresponds to a height that is below 
the 3rd percentile.   
8. Estimated glomerular filtration rate (eGFR) (77): The eGFR was calculated using the 
new "bedside" Schwartz equation eGFR = 36.5 x Height (cm)/Serum Creatinine 
(mmol/l). Reduced eGFR was defined as an eGFR less than 90 ml/min/1.73m
2
. The 
Siemens Advia 1800 enzymatic technique was used for the serum creatinine assay. 
9. Hypercholesterolaemia (78): serum total cholesterol and triglyceride levels were greater 
than or equal to the 95th percentile for age and sex. (Total serum cholesterol > 5.2 
mmol/l).  
10. Hyperglycaemia (79): A blood sugar level greater than 11.1 mmol/l (200 mg/dl).  
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2.7 Ethics and permission 
The study was conducted in full conformance with the principles of the Declaration of 
Helsinki, Good Clinical Practice and within the laws and regulations of South Africa. 
Consent was obtained from the head of the institution where the study data was collected. A 
submission to the Postgraduate Committee at the University of Witwatersrand and the Human 
Research Ethics Committee was made in order to obtain clearance for this study to take place 
and a clearance certificate was obtained (M150234). (Appendix B) 
2.8 Data Analysis 
All data were collated, checked and analysed using a computer based statistical package 
STATA version 13.1. The statistical analysis was performed by the primary investigator and 
the results were checked by a statistician. Continuous parameters were reported as mean and 
standard deviation while categorical variables were presented as percentages, bar charts and 
pie charts. Most variables were categorical due to the nature of the study design. These were 
reported using the proportion of total respondents. Associations between groups were 
determined using chi-square testing and bilateral Fisher’s exact tests. A confidence interval of 
95% was used and a p value < 0.05 was regarded as statistically significant.  
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3.  RESULTS 
A total of 163 children who met the study criteria were recruited. There were 97 (59.5%) 
males and 66 (40.5%) females with a male to female ratio of 1.46:1. (Table I) The mean age 
of the children at the time of presentation was 5.3 years ± 2.8.  
The mean follow up period (the period from the date of the onset of disease up until the time 
of data collection) was 60 months ± 36.9.  
At presentation, the majority of the patients were in the 2 to 6 year age group (71.2%). (Table 
I)  The majority of the patients in the cohort were of the black race (68.1%) and also the black 
race made up the highest number in all the age groups. (Table II) 
At initial presentation, 122 (74.8%) of the children had hypercholesterolaemia, 77 (47.2%) 
had hypertension, 32 (19.6%) had haematuria and 59 (36.2%) had an infection (respiratory 
tract infection 35, peritonitis 21 and UTI 3). 
 
3.1: The histopathological patterns of the disease 
 
Only 132 (80.9%) of the patients underwent a renal biopsy. The majority of the biopsies (90) 
were performed among the age group 2 to 6 years as shown in Table III. The most common 
indications for renal biopsy were steroid resistance (29.5%) and an atypical presentation such 
as the presence of hypertension, haematuria on presentation, or age greater than, or equal to, 
10 years (24.3%). (Figure 1) 
The biopsy rate was similar in the Black, White and Mixed racial groups (81.1%, 85.7% and 
87.5% respectively), while the Asian racial group had the lowest rate (72.7%). 
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Table I: The general characteristics of children with INS 
Sex n = 163 (%) 
Male 97 (59.5) 
Female 66(40.5) 
  
Race  
Black 111 (68.1) 
Asian 22 (13.5) 
Mixed 16 (9.8) 
White 14 (8.6) 
  
Age group at presentation (years)  
2 – 6 116 (71.2) 
7 – 10 36 (22.1) 
11 – 16 11 (6.7) 
  
Follow up period  (months)  
6 – 48 78 (47.8) 
49 – 84 37 (22.7) 
85 – 120 48 (29.5) 
 
 
                                                                                       24 
 
Table II: The age group distribution according to the racial groups 
Racial group n (%) 
Age group Black Asian Mixed Race White Total 
      
2 – 6 
71 
(61.2) 
(64.0) 
20 
(17.2) 
(90.8) 
14 
(12.1) 
(87.5) 
11 
(9.5) 
(78.6) 
116 
(100) 
(71.2) 
      
7 – 10 
30 
(83.3) 
(27.0) 
1 
(2.8) 
(4.6) 
2 
(5.6) 
(12.5) 
3 
(8.3) 
(21.4) 
36 
(100) 
(22.1) 
      
11 – 16 
10 
(90.9) 
(9.0) 
1 
(9.1) 
(4.6) 
0 
(0.0) 
(0.0) 
0 
(0.0) 
(0.0) 
11 
(100) 
(6.7) 
      
Total 
111 
(68.1) 
(100) 
22 
(13.5) 
(100) 
16 
(9.8) 
(100) 
14 
(8.6) 
(100) 
163 
(100) 
(100) 
 
 
 
29.50%
25%
21.20%
24.30%
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
30.00%
35.00%
SRNS = 39 FRNS = 33 SDNS = 28 Atypical = 32
Figure 1: The indications for renal biopsy
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The different histopathological types of INS seen according to the different racial groups are 
summarised in Table IV.  
There were no documented complications arising from the procedure noted in the medical 
records of these patients. 
132 patients underwent a renal biopsy. The most common histopathological lesion observed 
was MCD (52.3%) and the least common lesion observed was MesPGN (4.5%).  (Figure 2)  
The mean age at presentation of MCD and FSGS was similar, 64.5 months ± 28.3 and 67.0 
months ± 39.8 respectively. The mean age at presentation for MesPGN was higher (94.0 
months ± 28.6) when compared to the others.  
The black race had a similar incidence of MCD (38.8%) and FSGS (37.8%) while the white 
race had a higher incidence of MCD (64.3%) when compared to FSGS (14.3%). (Table IV) 
Mesangial proliferative glomerulonephritis was almost exclusively seen in the black race. 
When comparing the different racial groups with regards to the different histopathological 
types of INS, no significant statistical difference was detected (p=0.604). (Table IV) 
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0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
MCD= 69 FSGS= 57 MesPGN= 6
52.3%
43.2%
4.5%
Figure 2: The histopathological types of INS (n=132)
 
 
Table III: The histopathological types of INS according to age group 
Age group 
(year) 
 
Histopathological types of INS n (%) 
No Biopsy MCD FSGS MesPGN Total 
2 – 6 
26 
(22.4) 
(83.9) 
50 
(43.1) 
(72.5) 
37 
(31.9) 
(64.9) 
3 
( 2.6) 
(50.0) 
116 
(100) 
(71.2) 
      
7 – 10 
4 
(11.1) 
(12.9) 
17 
(47.2) 
(24.6) 
13 
(36.1) 
(22.8) 
2 
(5.6) 
(33.3) 
36 
(100) 
(22.1) 
      
11 – 16 
1 
(9.1) 
(3.2) 
2 
(18.2) 
(2.9) 
7 
(63.6) 
(12.3) 
1 
(9.1) 
(16.7) 
11 
(100) 
(6.7) 
      
Total 
31 
(19.0) 
(100) 
69 
(42.3) 
(100) 
57 
(35.0) 
(100) 
6 
(3.7) 
(100) 
163 
(100) 
(100) 
                      Fisher's exact, p = 0.116 
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Fisher's exact, p = 0.604 
 
.                        
 
 
3.2: The steroid response pattern 
All 163 patients of the cohort received prednisolone 2 mg/kg as a daily dose for at least 4 
weeks.  
The steroid response pattern was as follows; 94 (57.7%) patients had SSNS, and SRNS was 
present in 69 patients (42.3%). (Figure 3)  
Children with SSNS were further classified into frequent relapsers (≥2 relapses/6 months) 
and infrequent relapsers (<2 relapses/6 months).  
 
 
 
Table IV: The histopathological types of INS according to racial distribution 
Race 
Histological type n (%) 
No biopsy MCD FSGS MesPGN Total 
Black 
21 
(18.9) 
(67.7) 
43 
(38.8) 
(62.4) 
42 
(37.8) 
(73.7) 
5 
(4.5) 
(83.3) 
111 
(100) 
(68.1) 
      
Asian 
6 
(27.3) 
(19.3) 
9 
(40.9) 
(13.0) 
7 
(31.8) 
(12.3) 
0 
(0.0) 
(0.0) 
22 
(100) 
(13.5) 
      
Mixed  
2 
(12.5) 
(6.5) 
8 
(50.0) 
(11.6) 
6 
(37.5) 
(10.5) 
0 
(0.0) 
(0.0) 
16 
(100) 
(9.8) 
      
White 
2 
(14.3) 
(6.5) 
9 
(64.3) 
(13.0) 
2 
(14.3) 
(3.5) 
1 
(7.1) 
(16.7) 
14 
(100) 
(8.6) 
      
Total 
31 
(19.0) 
(100) 
69 
(42.3) 
(100) 
57 
(35.0) 
(100) 
6 
(3.7) 
(100) 
163 
(100) 
(100) 
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94 (57.7%)
69 (42.3%)
Figure 3: Pie chart showing distribution of steroid response patterns
SSNS
SRNS
 
 
 
 
 
 
 
 
 
Table V: The distribution of the different response patterns to steroid therapy 
Response pattern  (n) % 
IF 55 33.7 
FR 10 6.1 
SDNS 29 17.8 
SRNS 69 42.3 
Total 163 (100) 
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 Table VI: The steroid response patterns according to the histopathological types of INS  
 Histological type n (%) 
Clinical type 
No Biopsy MCD FSGS MesPGN Total 
SSNS 
20 
(30.8) 
(64.5) 
39 
(60) 
(56.5) 
6 
(9.2) 
(10.5) 
0 
(0.0) 
(0.0) 
65 
(100) 
(39.9) 
      
SDNS 
5 
(17.2) 
(16.1) 
18 
(62.1) 
(26.1) 
6 
(20.7) 
(10.5) 
0 
(0.0) 
(0.0) 
29 
(100) 
(17.8) 
      
SRNS 
6 
(8.7) 
(19.4) 
12 
(17.4) 
(17.4) 
45 
(65.2) 
(79.0) 
6 
(8.7) 
(100) 
69 
(100) 
(42.3) 
      
Total 
31 
(19.0) 
(100) 
69 
(42.3) 
(100) 
57 
(35.0) 
(100) 
6 
(3.7) 
(100) 
163 
(100) 
(100) 
      
Fisher's exact, p < 0.001 
 
 
 
Table VII: The relationship between the racial groups and the steroid response patterns 
 Steroid response pattern (%) 
Race SSNS SDNS SRNS Total 
Black 39 
(35.1) 
(60.0) 
21 
(18.9) 
(72.5) 
51 
(46.0) 
(73.9) 
111 
(100) 
(68.1) 
 
     
Asian 13 
(59.1) 
(20.0) 
3 
(13.6) 
(10.3) 
6 
(27.3) 
(8.7) 
22 
(100) 
(13.5) 
 
     
Mixed  
 
6 
(37.5) 
(9.2) 
2 
(12.5) 
(6.9) 
8 
(50.0) 
(11.6) 
16 
(100) 
(9.8) 
 
     
White 7 
(50.0) 
(10.8) 
3 
(21.4) 
(10.3) 
4 
(28.6) 
(5.8) 
14 
(100) 
(8.6) 
 
     
Total 65 
(39.9) 
(100) 
29 
(17.8) 
(100) 
69 
(42.3) 
(100) 
163 
(100) 
(100) 
           Fisher's exact, p = 0.434 
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Ninety four (57.7%) patients responded to their first steroid course and, of those, 55 (33.7%) 
turned out to be infrequent relapsers and 10 (6.1%) became frequent relapsers. (Table V) 
Twenty nine (17.8%) of the group of patients who were initially steroid sensitive later became 
steroid dependent, while 69 (42.3%) of the patients were steroid resistant from the outset. (Table 
V) 
Table VI shows the various steroid response patterns of INS according to the different 
histopathological types. Minimal change disease was the most common type (60%) seen in 
SSNS, while FSGS was the most common type (65.2%) observed in patients who had SRNS. 
There was a statistically significant association between the various steroid response patterns and 
the different histopathological types. 
Six patients (8.7%) of the SRNS group were not biopsied. All six defaulted from follow up and 
subsequently presented at a later stage to our division with severe renal dysfunction requiring 
renal replacement therapy. (Table VI) 
Table VII shows the relationship between the different racial groups and the various steroid 
response patterns. SSNS was seen more in the Asian (59.1%) and white groups (50%) while the 
mixed race and black racial groups had a higher incidence of SRNS (50% and 46%respectively). 
(Table VII) 
There was no statistically significant association seen between the various racial groups and the 
different steroid response patterns (p=0.434). 
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Fisher's exact, p < 0.001                                                                                                                                                    
.                             
 
 
Table IX:  The relationship between racial groups and outcome of INS at 60 months mean follow up period  
 
 
 
Race 
Sustained 
remission 
without any 
treatment 
Remission on 
steroid 
treatment 
alone 
Remission on 
SSDs and 
steroid 
treatment 
FRNS  
Resistant to 
all treatment 
Total 
Black 
34 
(30.7) 
(64.2) 
22 
(19.8) 
(78.6) 
5 
(4.5) 
(55.6) 
5 
(4.5) 
(41.6) 
45 
(40.5) 
(73.8) 
111 
(100.0) 
(68.1) 
Asian 
11 
(50.0) 
(20.8) 
2 
(9.1) 
(7.1) 
1 
(4.6) 
(11.1) 
3 
(13.6) 
(25.0) 
5 
(22.7) 
(8.2) 
22 
(100.0) 
(13.5) 
Mixed 
 
3 
(18.7) 
(5.7) 
1 
(6.3) 
(3.6) 
2 
(12.5) 
(22.2) 
2 
(12.5) 
(16.7) 
8 
(50.0) 
(13.1) 
16 
(100.0) 
(9.8) 
White 
5 
(35.7) 
(9.3) 
3 
(21.4) 
(10.7) 
1 
(7.2) 
(11.1) 
2 
(14.3) 
(16.7) 
3 
(21.4) 
(4.9) 
14 
(100.0) 
(8.6) 
Total 
53 
(32.5) 
(100.0) 
28 
(17.2) 
(100.0) 
9 
(5.5) 
(100.0) 
12 
(7.4) 
(100.0) 
61 
(37.4) 
(100.0) 
163 
(100.0) 
(100.0) 
.                         .                           Fisher's exact, p = 0.135                                                                                                                                                    
 
Table VIII: The relationship between steroid response patterns and outcome of INS at 60 months mean follow up period  
 
 
Sustained 
remission 
without any 
treatment 
Remission on 
steroid 
treatment alone 
Remission on 
SSDs and 
steroid 
treatment 
FRNS  
Resistant to 
all treatment 
Total 
SSNS 
53 
(81.5) 
(100) 
1 
(1.5) 
(3.6) 
0 
(0.0) 
(0.0) 
10 
(15.5) 
(83.3) 
1 
(1.5) 
(1.6) 
65 
(100.0) 
(39.9) 
SDNS 
0 
(0.0) 
(0.0) 
27 
(93.1) 
(96.4) 
2 
(6.9) 
(22.2) 
0 
(0.0) 
(0.0) 
0 
(0.0) 
(0.0) 
29 
(100.0) 
(17.8) 
SRNS 
0 
(0.0) 
(0.0) 
0 
(0.0) 
(0.0) 
7 
(10.1) 
(77.8) 
2 
(2.9) 
(16.7) 
60 
(87.0) 
(98.4) 
69 
(100.0) 
(42.3) 
Total 
53 
(32.5) 
(100.0) 
28 
(17.2) 
(100.0) 
9 
(5.5) 
(100.0) 
12 
(7.4) 
(100.0) 
61 
(37.4) 
(100.0) 
163 
(100.0) 
(100.0) 
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Steroid sparing drugs (SSDs) were used in patients who were steroid dependent and steroid 
resistant. Nine of the SRNS patients were able to achieve remission with the use of SSDs. Seven 
of these remained in remission afterwards on SSDs and corticosteroid treatment, while two 
developed a frequently relapsing picture while on SSDs and corticosteroid treatment. (Table 
VIII)        
The highest rate of resistance to all treatment after a mean follow up of 60 months was seen 
among children of the mixed race and black racial groups (50.0% and 40.5% respectively). 
(Table IX)  
3.3: The complications from the disease and/or the treatment 
The most common complications observed were stunted growth (52.1%), hypertension (47.2%), 
reduced eGFR (25.8%), peritonitis (12.9%) and pulmonary tuberculosis (8.6%). Other 
complications such as thromboembolic phenomenon (TEP), AKI and hypothyroidism were less 
common. (Table X) 
A more detailed breakdown of the group with a reduced eGFR can be seen in Figure 4. 
Hypertension, peritonitis, reduced eGFR and stunted growth were most commonly seen in 
patients with FSGS, and there was a statistically significant association between the presence of 
these complications and the various steroid response patterns and different histopathological 
types. (Table XI and XII) 
Hypertension, peritonitis, reduced eGFR and stunted growth were most common in black 
children with INS when compared to the other racial groups but, of these complications, only 
hypertension showed any statistically significant association when comparing the different racial 
groups. (Table XIII)       
                                                                                       33 
 
Table X: The complications of INS 
 n (%) 
Hypertension  
Yes   77 (47.2) 
No 86 (52.8) 
Peritonitis  
Yes 21 (12.9) 
No 142 (87.1) 
  
Reduced estimated glomerular filtration rate (eGFR)*  
Yes 42  (25.8) 
No 121 (74.2) 
  
Thromboembolic phenomenon  
Yes 4 (2.5) 
No 159 (97.5) 
Acute kidney injury  
Yes 1 (0.6) 
No 162 (99.4) 
Hypothyroidism  
Yes 1 (0.6) 
No 162 (99.4) 
Stunted growth  
Yes 85 (52.1) 
No 78 (47.9) 
Pulmonary tuberculosis  
Yes 14 (8.6) 
No 149 (91.4) 
Hyperglycaemia  
Yes 4 (2.5) 
No 159 (97.5) 
Psychosis  
Yes 2 (1.2) 
No 161 (98.8) 
Chicken pox  
Yes 1 (0.6) 
No 162 (99.4) 
Obesity  
Yes 1 (0.6) 
No 162 (99.4) 
Cataract  
Yes 1 (0.6) 
No 162 (99.4) 
* See Figure 4 for the breakdown of reduced eGFR.
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9 (21.5%)
4 (9.5%)
4 (9.5%)
25 (59.5%)
60 - 89
30 - 59
15 - 29
<15
Figure 4: Breakdown of group with a reduced eGFR (ml/min/1.73m2)(n=42)
 
 
 
Table XI: The relationship between the common complications of INS and the 
histopathological types 
 
Histopathological types = n (%) 
Complications 
MCD 
(n=69) 
FSGS 
(n=57) 
MesPGN 
(n=6) 
P value 
Hypertension 14 46 5 <0.001 
Peritonitis 6 12 2 0.044 
Reduced eGFR 6 24 5 <0.001 
Stunted growth 25 43 5 <0.001 
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Table XIII: The relationship between the common complications of INS and the different 
race groups 
Race group = n (%) 
Complications 
Black 
(n = 111) 
Asian 
(n = 22) 
Mixed  
(n =16) 
White 
(n = 14) 
P value 
Hypertension 59 8 8 2 0.030 
Peritonitis 15 2 3 1 0.795 
Reduced eGFR 34 3 4 1 0.143 
Stunted growth 60 12 7 6 0.778 
 
Table XII: The relationship between the common complications of INS and the steroid 
response patterns 
 Steroid response pattern 
Complications SSNS 
(n=65) 
SDNS 
(n=29) 
SRNS 
(n=64) 
P value 
Hypertension 12 6 59 <0.001 
Peritonitis 2 3 16 <0.001 
Reduced eGFR 4 2 36 <0.001 
Stunted growth 20 11 54 <0.001 
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4. DISCUSSION 
In this single centre study, we did a 10 year review of children with idiopathic nephrotic 
syndrome (INS). One hundred and sixty three children met the selection criteria and their records 
were reviewed.  
The study found a male preponderance with a male: female ratio of 1.46:1 which is similar to 
various studies done elsewhere. (5,6,12,41,45) The mean age at presentation was 5.3 years ± 2.8. 
This finding is lower than that described by Bhimma et al in Durban (6.2 years) and other studies 
reported from India (7.9 years), New Zealand (6.1 years) and Pakistan (7.26 years). (5,12,17,80) 
A study from the USA reported a similar age at presentation (5.3 years) to our study, (11)  while 
studies from Iran and Turkey reported a lower age at presentation of 4.9 years and 4.6 years 
respectively. (9,45) These differences in the age of presentation may be due to ethnic differences 
in the patient demographics of the various studies mentioned above. In the case of the studies 
from India, Pakistan and New Zealand, the majority of the patients were Asian, whereas the 
study from the USA had a much more diverse patient group in terms of ethnicity than the other 
studies. Although we expected our study cohort to have a similar age of presentation to that of 
the Durban study, the Durban study had a higher percentage of Asian patients in their cohort than 
we had in ours and it is possible that this made their mean age of presentation closer to that 
observed in the studies from India, Pakistan and New Zealand than to that of our study. 
 Our study found the highest rate of INS in the age group 2 to 6 years. This is similar to that 
which has been reported from Pretoria, Iran and New Zealand and other Western countries. 
(1,6,9,17)   
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In our study, black children made up the predominant race group (68.1%). This is in keeping 
with the racial distribution of the general population of Johannesburg. Similarly, the study from 
Pretoria also reported a cohort made up predominantly of black patients (77.7%). (6) The study 
from Pretoria had only two racial groups in the study, white and black, and this may explain the 
greater percentage of black patients reported in their findings as compared to our study. On the 
contrary, the study from Durban reported the Indian (Asian) race to be the predominant group 
(52.5%), with the black race representing only 43.3% of the patients. (5) 
There were various indications for renal biopsy in our group of patients; the most common were 
steroid resistance (29.5%), a frequently relapsing picture (25%) and an atypical presentation 
(24.3%). Other studies have also documented these same reasons as the most frequent 
indications for biopsy. (9,11,12,17,41,45,80) Some units in South Africa had a policy to biopsy 
all patients from the black race group, however this policy was not followed in our unit. (5,6) 
Minimal change disease (MCD) accounted for the most common histopathologic variant 
observed in our cohort (52.3%). This is similar to the report from Pakistan where MCD 
accounted for 51.2%. (80). Other studies, including previous South African studies, have 
reported a much lower rate of MCD (<36%). (5,6,12,41,45) It is possible that these apparent 
differences in the rate of MCD in children may be due to variations in the indications for biopsy 
in the different studies (where the most common indication was steroid resistance) rather than 
actual differences in the rate of MCD in the various population groups studied.  
Focal segmental glomerulosclerosis (FSGS) was found to have a rate of 43.2% in our study 
which is higher than the rates reported in previous South African studies namely 28.5% in the 
Durban study, 25% in the Pretoria study and 31.3% in a study from Johannesburg. (5,6,10) One 
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possible reason for this finding may be the decline of infection related nephrotic syndrome (NS) 
which up until now was one of the most common causes of NS in children and presented as other 
histopathological subtypes such as Membranous Nephropathy (MN) and Membranoproliferative 
glomerulonephritis (MPGN). (5) Other possible reasons include the postulation that suggests the 
transition of MCD to FSGS in selected cases, although this has yet to be proven, and the very 
real possibility of misdiagnosing FSGS as MCD due to technical challenges or sampling error. 
(1,2) 
As has been also noted in previous studies, in our cohort, the age of presentation of FSGS was 
most common in the age group of 2-6 years. (5,45) 
Mesangial proliferative glomerulonephritis (MesPGN) was the least common histopathologic 
variant observed in our study (4.5%). Even though higher rates have been reported from India 
(11.4%), Turkey (17%) and the US (25%), our findings are in keeping with rates reported in 
previous South African studies. (5,6,11,12,45)  
Ethnicity has been implicated in playing a role in the histopathological types of INS. Studies 
with diverse patient cohorts have reported a higher rate of FSGS in the black race group. (5,6,11) 
Similarly, in our group FSGS made up a larger proportion of cases in the black race group when 
compared to the other race groups.  
Despite the inhomogeneous nature of our cohort, we observed an initial response rate to steroid 
therapy of 57.7% and a steroid resistance rate of 42.3%. This is almost similar to the steroid 
response pattern reported from Pakistan, even though they had a much more homogeneous 
cohort. (80) Studies from New Zealand and Iran reported much higher steroid response rates of 
80.4% and 75.2% respectively. (9,17) 
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A similar rate of frequent relapse (10.6%) and steroid dependence (17.8%) was observed in our 
steroid sensitive group of patients to that which was reported in the study from New Zealand. 
(17) 
Although we observed a high rate of steroid resistance among the black racial group in our study, 
this group also had a high rate of steroid sensitivity (35.1%). This is contrary to reports from 
previous South African studies and the traditional belief that most black children are steroid 
resistant. (5,6,10) 
We also observed that the mixed racial group exhibited a similar steroid response pattern to the 
black racial group. 
A small fraction of the MCD group was steroid resistant (17.4%), and likewise a small fraction 
of the FSGS group was steroid sensitive (21%). These findings are in keeping with findings 
reported elsewhere. (9,12,17,45,80) 
Unexpectedly, we did not find any significant statistical association between racial distribution 
and the histopathological types, or any association between racial distribution and steroid 
response pattern.  
Various complications were observed in our cohort; these were due to the disease itself and also 
related to adverse effects of the treatment administered to the patients. The most common 
complication observed was hypertension which was found in 47.2% of the patients. This finding 
is similar to the rate reported by the study from Pretoria (47.8%). (6)  High rates of hypertension 
were seen mostly in patients with FSGS (46/57), SRNS (59/64) and in those of the black and 
mixed race racial groups (59/111 and 8/16 respectively). In addition, we also found a statistically 
significant association between hypertension and racial group. The Durban study reported a very 
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low rate of hypertension (2.2%). We believe that this is because, in that study, hypertension was 
only mentioned in the context of steroid related complications, whereas in our study we reported 
on hypertension as a complication across the board. (5)  
Peritonitis is a common complication seen in INS. In our study, 12.9% of the patients had one or 
more episodes of peritonitis. This rate is higher than what has been reported in previous South 
African studies where the reported rate was closer to 7%. (5,6)  
Previous reports have noted a reduced eGFR (<90ml/min/1.73m
2
) in patients with SRNS. These 
patients are at risk of progression to ESKD (<15ml/min/1.73m
2
). (6,41) At least a quarter of our 
patients (25.8%) had a reduced eGFR but this rate is lower than what was reported in the study 
from Pretoria (35.8%). (6) Among our cohort with reduced eGFR (42/163), 25 (59.5%) were 
already in ESRD. We also observed that six patients with steroid resistance, who defaulted at 
some point from follow-up, were amongst the group with ESRD.  
A high rate of stunted growth was observed in about half of our cohort (52.1%). This very 
important finding was observed as a late outcome of the disease or treatment.  The finding may 
be partly explained by longer courses of steroids given to patients with SRNS, in an attempt to 
effect remission, and also because of the high rate of a reduced eGFR in our cohort. Furthermore, 
in our centre, patients are maintained on low dose steroid therapy even when in remission or on 
steroid sparing drugs.  
Thrombo-embolic phenomena were observed in only four children in our cohort (2.5%), a rate 
similar to that noted in reports from elsewhere. (6,17) This low rate may be due to the routine use 
of low dose aspirin in our patients with INS. 
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It is often difficult in children to obtain a confirmatory diagnosis of pulmonary tuberculosis 
(PTB) due to the low yield from specimens (sputum and blood) sent for laboratory investigation. 
For this reason most diagnoses are made based on clinical suspicion and then a response to 
empirical treatment. In our cohort 14 children (8.6%) were treated for PTB based on clinical 
signs. None had sputum positive PTB. This rate is much lower than what has been previously 
reported in South Africa. (7) Possible reasons for this difference may include an overall 
improved health status of the indigent community in South Africa, better detection and treatment 
of PTB in the general community and the increased use of HAART in the general population. 
(81) It is also possible that the authors of the previous study may have had a much higher index 
of suspicion for PTB than did our unit. (7)  
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5. CONCLUSIONS 
Our cohort demonstrated the same age pattern at presentation of INS as has been documented 
previously, with the age group 2-6 years being the most common age of presentation, and the 
racial distribution observed in our study is in keeping with that of the general population pattern 
of Johannesburg. 
We found higher rates of MCD, and also of favourable steroid response patterns, in our black 
race group than have been previously reported from South Africa.  
Of concern is our finding of an increase in the rate of FSGS in all the racial groups when 
compared to previous studies and we are not sure if this represents a new trend that FSGS is 
increasing in our population. If our finding of an increase in the rate of FSGS when compared to 
previous South African studies is real, this may mean that in the future we might begin to see an 
increase in the rate of steroid resistance among South African children with INS.  
In our study the highest rates of a reduced eGFR were observed among those patients with SRNS 
and among those with FSGS. Given the high rate of SRNS and FSGS in our group of black 
patients, there is concern that this group would be at a high risk of going on to develop a reduced 
eGFR in the future. 
Even though hypertension was the most common complication observed in our cohort, a very 
high rate of stunted growth was also observed. Based on this we will be limiting the routine use 
of long term steroid therapy in our steroid resistant patients in the future. 
We hope that the results of this research will be useful in improving the care of children with 
INS in our unit. 
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6. RECOMMENDATIONS 
Our study did not include patients from the private sector who are on medical aids. It is possible 
that these patients, who are more likely to come from better socio economic circumstances, may 
have a slightly different spectrum of disease than that seen in our cohort. Also, another limitation 
of our study is that it is of a retrospective nature. In light of the above, we would suggest that the 
time has come for a prospective, multicentre, national study on childhood INS in South Africa. 
Specific factors to be addressed might include a careful documentation of the clinical 
presentation and histopathological findings of the disease, genetic evaluation, and then an 
assessment of the steroid response patterns to strict study protocols. A study of this nature will 
give us a clearer of picture of the rate of FSGS and steroid responsiveness in South Africa, and 
will also enable us to tailor treatment regimens unique to our patients.  
Unfortunately, the nature of our data was such that we could not compare the response rates of 
our patients to the other agents used in SRNS. We would suggest that this be taken into 
account when planning further research on this topic. 
In view of the high rates of short stature observed in our study we will be adjusting our treatment 
regimes to shorter and lower dose courses for steroid responsive INS, and will be withdrawing 
steroids sooner in patients who have shown themselves to be steroid resistant. The question of 
how long one should persist with steroid therapy, and at what dose, in South African children 
with SRNS has not yet been clearly answered, hence our recommendation for the performance of 
a multicentre national trial. 
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APPENDIX A: Data collection sheet  
1. General information 
Study number  
Enrolment date  
Date of birth  
Age (years)  
Sex 
       Male                              Female 
Race 
       Black                             White       
       Mixed                            Asian 
 
 
 
2. Medical history 
Age at diagnosis (years)  
Follow up period (months)  
Atypical presentation 
       Haematuria           Hypertension 
Steroid response 
      SSNS                     SRNS 
Relapse       FRNS                    IFRNS               SDNS 
Renal biopsy 
      Yes                        No 
Histopathological report 
      MCD                     FSGS                 MesPGN 
Steroid sparing drugs (SSDs)        yes                          no 
Type of SSDs 
      Cyclophosphamide                 Chlorambucil 
      Cyclosporine                          Tacrolimus 
      MMF                                       Others 
Renal biopsy 
       Yes                       No 
  
  
   
       
 
  
   
   
  
 
 
 
 
 
 
  
  
Comments: 
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         3. Outcome of treatment                                  
 
 
 
 
 
 
 
4. COMPLICATIONS 
Hypertension 
       Yes                       No 
Stunting 
       Yes                       No 
Infection 
       Yes                       No 
Types of infection 
       RTI                       Peritonitis  
       PTB                      Chicken pox 
 
       Others 
Reduced eGFR (<90 ml/min/1.73m
2
) 
       Yes                       No 
Breakdown of eGFR <90 ml/min/1.73m
2
 
       60-89                     30-59                  
       15-29                      <15                                                        
Hyperglycaemia        Yes                       No 
Thromboembolic phenomenon        Yes                       No 
Acute kidney injury        Yes                       No 
Hypothyroidism        Yes                       No 
Psychosis        Yes                       No 
Obesity        Yes                       No 
Cataract        Yes                       No 
             
 
 
Sustained remission without 
 any treatment  
 Remission on only steroid 
 treatment  
Remission on SSDs and steroid 
treatment  
Frequent relapse to all  
treatment  
Resistant to all treatment  
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APPENDIX B: ETHICS CLEARANCE CERTIFICATE 
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